ESR1 and in situ carcinoma: In vivo, CB839 or ERA did not enhance CIS chemotherapy in resistant tumors (P > 0.05 comparing CIS vs. CB839+CIS or ERA+CIS, Fig. 6F) despite the data that CIS plus CB839 or ERA induced a moderate growth delay compared to the CNTRL.